Charbel Moussa

Last updated on 2016-07-28T15:05+0300.

About this image

sign

Quotes... Extracted quotes from

Charbel Moussa explains : "The current data are in agreement with previous preclinical and other clinical studies at Georgetown suggesting nilotinib is a potential disease-modifying drug that triggers autophagy of neurotoxic proteins including Aβ40/, Aβ42, and phospho tau-181," External link

medicalxpress Friday, May 29, 2020 10:52:00 AM EAT

Charbel Moussa adds : "The increase in mood swings with 300 mg nilotinib is associated with dose-dependent increases of brain dopamine, suggesting that 150 mg nilotinib is the optimal dosage to investigate in a future Alzheimer study," External link

medicalxpress Friday, May 29, 2020 10:52:00 AM EAT

Charbel Moussa explains : "The current data are in agreement with previous preclinical and other clinical studies at Georgetown suggesting nilotinib is a potential disease-modifying drug that triggers autophagy of neurotoxic proteins including Aβ40/, Aβ42, and phospho tau-181," External link

eurekalert Friday, May 29, 2020 7:31:00 AM EAT

Charbel Moussa adds : "The increase in mood swings with 300 mg nilotinib is associated with dose-dependent increases of brain dopamine, suggesting that 150 mg nilotinib is the optimal dosage to investigate in a future Alzheimer study," External link

eurekalert Friday, May 29, 2020 7:31:00 AM EAT

Charbel Moussa says : "Nilotinib is increasing the availability of stored dopamine in the brain," External link

npr Monday, December 16, 2019 8:08:00 PM EAT

Charbel Moussa says : "Our study shows that at these lower doses, nilotinib does not seem to cause Abl inhibition, suggesting it shouldn't have the same safety concerns that are potentially associated with Abl inhibition as might be the case at higher doses," External link

eurekalert Monday, December 16, 2019 8:01:00 PM EAT

Charbel Moussa explains : "Individually, these are very important findings, but taken together, it means that the clearance of these neurotoxic proteins may not solely depend on Abl inhibition -- other tyrosine kinases or alternate mechanisms may be involved," External link

eurekalert Monday, December 16, 2019 8:01:00 PM EAT

Charbel Moussa says : "Our study shows that at these lower doses, nilotinib does not seem to cause Abl inhibition, suggesting it shouldn't have the same safety concerns that are potentially associated with Abl inhibition as might be the case at higher doses," External link

medicalxpress Monday, December 16, 2019 7:16:00 PM EAT

Charbel Moussa explains : "Individually, these are very important findings, but taken together, it means that the clearance of these neurotoxic proteins may not solely depend on Abl inhibition—other tyrosine kinases or alternate mechanisms may be involved," External link

medicalxpress Monday, December 16, 2019 7:16:00 PM EAT

Charbel Moussa says : "We are repurposing TK inhibitor drugs toward neurodegenerative disorders—the vast majority of which feature toxic buildup in brain cells," "Our studies suggest this strategy works in neurons that are diseased but remain vital enough to be reprogrammed" External link

medicalxpress Wednesday, October 23, 2019 1:35:00 PM EAT

Charbel Moussa added : "This agent has undergone extensive testing in several animal models of neurodegeneration, and it represents a good candidate that should be investigated in first-in-human trials. We have so far shown that this agent has a superior efficacy to clear neurotoxic proteins in animals compared to similar agents, and we identified DDRs as a preferential and optimal drug target. The next step is to investigate drug toxicity in order to obtain regulatory permission for human application," External link

medicalxpress Wednesday, October 23, 2019 1:35:00 PM EAT

Charbel Moussa says : "We are repurposing TK inhibitor drugs toward neurodegenerative disorders -- the vast majority of which feature toxic buildup in brain cells," "Our studies suggest this strategy works in neurons that are diseased but remain vital enough to be reprogrammed" External link

sciencedaily Tuesday, October 22, 2019 10:19:00 PM EAT

Charbel Moussa added : "This agent has undergone extensive testing in several animal models of neurodegeneration, and it represents a good candidate that should be investigated in first-in-human trials. We have so far shown that this agent has a superior efficacy to clear neurotoxic proteins in animals compared to similar agents, and we identified DDRs as a preferential and optimal drug target. The next step is to investigate drug toxicity in order to obtain regulatory permission for human application," External link

sciencedaily Tuesday, October 22, 2019 10:19:00 PM EAT

Charbel Moussa says : "We are repurposing TK inhibitor drugs toward neurodegenerative disorders -- the vast majority of which feature toxic buildup in brain cells," "Our studies suggest this strategy works in neurons that are diseased but remain vital enough to be reprogrammed" External link

eurekalert Tuesday, October 22, 2019 9:51:00 PM EAT

Charbel Moussa added : "This agent has undergone extensive testing in several animal models of neurodegeneration, and it represents a good candidate that should be investigated in first-in-human trials. We have so far shown that this agent has a superior efficacy to clear neurotoxic proteins in animals compared to similar agents, and we identified DDRs as a preferential and optimal drug target. The next step is to investigate drug toxicity in order to obtain regulatory permission for human application," External link

eurekalert Tuesday, October 22, 2019 9:51:00 PM EAT

Charbel Moussa says : "When the drug is used, levels of these breakdown molecules quickly rise. This is what we also found in our preclinical studies and proof of concept clinical trial," "This is exciting because this kind of potential treatment for Parkinson's could increase use of a patient's own dopamine instead of using or periodically increasing drugs that mimic dopamine" External link

medicalxpress Wednesday, March 20, 2019 7:31:00 AM EAT

Charbel Moussa says : "When the drug is used, levels of these breakdown molecules quickly rise. This is what we also found in our preclinical studies and proof of concept clinical trial," "This is exciting because this kind of potential treatment for Parkinson's could increase use of a patient's own dopamine instead of using or periodically increasing drugs that mimic dopamine" External link

eurekalert Tuesday, March 12, 2019 9:27:00 PM EAT

Charbel Moussa said : "Overexpression of USP13 in post-mortem brains with Parkinson's disease was never discovered before this work. Its presence indicates that this molecule might reduce parkin's ability to tag proteins with ubiquitin or may strip ubiquitin away from certain molecules like alpha-synuclein, resulting in accumulation of toxic clumps in the brain," External link

medicalxpress Monday, February 4, 2019 9:45:00 AM EAT

Charbel Moussa added : "Our discovery clearly indicates that inhibition of USP13 is a strategic step to activate parkin and counteract alpha-synuclein de-ubiquitination, to increase toxic protein clearance" "Our next step is to develop a small molecule inhibitor of USP13 to be used in combination with nilotinib in order to maximize protein clearance in Parkinson's and other neurodegenerative diseases" External link

medicalxpress Monday, February 4, 2019 9:45:00 AM EAT



Key Titles and Phrases Count Lang Last Seen
investigator66.67%EN07/13/201613/07/2016
senior researcher33.33%EN07/12/201612/07/2016
Names Lang Count
Charbel MoussaEN75.00%
Charbel MoussaPT25.00%


 
Show/hide duplicate news articles.
<<10<12345678910>>>10
 
Show/hide duplicate news articles.
<<10<12345678910>>>10

Tools

Load latest edition

Saturday, September 19, 2020

7:34:00 PM EAT

Languages Collapse menu...Expand menu...

Select your languages

af
am
ar
de
en
es
fr
ha
pt
rw
sw
all
Show additional languagesHide additional languages

Interface:

Legend Collapse menu...Expand menu...


Quotes... Explore Relations


EMM Visual Explorer


AfricaBrief

Charbel Moussa

Last updated on 2016-07-28T15:05+0300.

About this image

sign

Quotes... Extracted quotes from

Charbel Moussa explains : "The current data are in agreement with previous preclinical and other clinical studies at Georgetown suggesting nilotinib is a potential disease-modifying drug that triggers autophagy of neurotoxic proteins including Aβ40/, Aβ42, and phospho tau-181," External link

medicalxpress Friday, May 29, 2020 10:52:00 AM EAT

Charbel Moussa adds : "The increase in mood swings with 300 mg nilotinib is associated with dose-dependent increases of brain dopamine, suggesting that 150 mg nilotinib is the optimal dosage to investigate in a future Alzheimer study," External link

medicalxpress Friday, May 29, 2020 10:52:00 AM EAT

Charbel Moussa explains : "The current data are in agreement with previous preclinical and other clinical studies at Georgetown suggesting nilotinib is a potential disease-modifying drug that triggers autophagy of neurotoxic proteins including Aβ40/, Aβ42, and phospho tau-181," External link

eurekalert Friday, May 29, 2020 7:31:00 AM EAT

Charbel Moussa adds : "The increase in mood swings with 300 mg nilotinib is associated with dose-dependent increases of brain dopamine, suggesting that 150 mg nilotinib is the optimal dosage to investigate in a future Alzheimer study," External link

eurekalert Friday, May 29, 2020 7:31:00 AM EAT

Charbel Moussa says : "Nilotinib is increasing the availability of stored dopamine in the brain," External link

npr Monday, December 16, 2019 8:08:00 PM EAT

Charbel Moussa says : "Our study shows that at these lower doses, nilotinib does not seem to cause Abl inhibition, suggesting it shouldn't have the same safety concerns that are potentially associated with Abl inhibition as might be the case at higher doses," External link

eurekalert Monday, December 16, 2019 8:01:00 PM EAT

Charbel Moussa explains : "Individually, these are very important findings, but taken together, it means that the clearance of these neurotoxic proteins may not solely depend on Abl inhibition -- other tyrosine kinases or alternate mechanisms may be involved," External link

eurekalert Monday, December 16, 2019 8:01:00 PM EAT

Charbel Moussa says : "Our study shows that at these lower doses, nilotinib does not seem to cause Abl inhibition, suggesting it shouldn't have the same safety concerns that are potentially associated with Abl inhibition as might be the case at higher doses," External link

medicalxpress Monday, December 16, 2019 7:16:00 PM EAT

Charbel Moussa explains : "Individually, these are very important findings, but taken together, it means that the clearance of these neurotoxic proteins may not solely depend on Abl inhibition—other tyrosine kinases or alternate mechanisms may be involved," External link

medicalxpress Monday, December 16, 2019 7:16:00 PM EAT

Charbel Moussa says : "We are repurposing TK inhibitor drugs toward neurodegenerative disorders—the vast majority of which feature toxic buildup in brain cells," "Our studies suggest this strategy works in neurons that are diseased but remain vital enough to be reprogrammed" External link

medicalxpress Wednesday, October 23, 2019 1:35:00 PM EAT

Charbel Moussa added : "This agent has undergone extensive testing in several animal models of neurodegeneration, and it represents a good candidate that should be investigated in first-in-human trials. We have so far shown that this agent has a superior efficacy to clear neurotoxic proteins in animals compared to similar agents, and we identified DDRs as a preferential and optimal drug target. The next step is to investigate drug toxicity in order to obtain regulatory permission for human application," External link

medicalxpress Wednesday, October 23, 2019 1:35:00 PM EAT

Charbel Moussa says : "We are repurposing TK inhibitor drugs toward neurodegenerative disorders -- the vast majority of which feature toxic buildup in brain cells," "Our studies suggest this strategy works in neurons that are diseased but remain vital enough to be reprogrammed" External link

sciencedaily Tuesday, October 22, 2019 10:19:00 PM EAT

Charbel Moussa added : "This agent has undergone extensive testing in several animal models of neurodegeneration, and it represents a good candidate that should be investigated in first-in-human trials. We have so far shown that this agent has a superior efficacy to clear neurotoxic proteins in animals compared to similar agents, and we identified DDRs as a preferential and optimal drug target. The next step is to investigate drug toxicity in order to obtain regulatory permission for human application," External link

sciencedaily Tuesday, October 22, 2019 10:19:00 PM EAT

Charbel Moussa says : "We are repurposing TK inhibitor drugs toward neurodegenerative disorders -- the vast majority of which feature toxic buildup in brain cells," "Our studies suggest this strategy works in neurons that are diseased but remain vital enough to be reprogrammed" External link

eurekalert Tuesday, October 22, 2019 9:51:00 PM EAT

Charbel Moussa added : "This agent has undergone extensive testing in several animal models of neurodegeneration, and it represents a good candidate that should be investigated in first-in-human trials. We have so far shown that this agent has a superior efficacy to clear neurotoxic proteins in animals compared to similar agents, and we identified DDRs as a preferential and optimal drug target. The next step is to investigate drug toxicity in order to obtain regulatory permission for human application," External link

eurekalert Tuesday, October 22, 2019 9:51:00 PM EAT

Charbel Moussa says : "When the drug is used, levels of these breakdown molecules quickly rise. This is what we also found in our preclinical studies and proof of concept clinical trial," "This is exciting because this kind of potential treatment for Parkinson's could increase use of a patient's own dopamine instead of using or periodically increasing drugs that mimic dopamine" External link

medicalxpress Wednesday, March 20, 2019 7:31:00 AM EAT

Charbel Moussa says : "When the drug is used, levels of these breakdown molecules quickly rise. This is what we also found in our preclinical studies and proof of concept clinical trial," "This is exciting because this kind of potential treatment for Parkinson's could increase use of a patient's own dopamine instead of using or periodically increasing drugs that mimic dopamine" External link

eurekalert Tuesday, March 12, 2019 9:27:00 PM EAT

Charbel Moussa said : "Overexpression of USP13 in post-mortem brains with Parkinson's disease was never discovered before this work. Its presence indicates that this molecule might reduce parkin's ability to tag proteins with ubiquitin or may strip ubiquitin away from certain molecules like alpha-synuclein, resulting in accumulation of toxic clumps in the brain," External link

medicalxpress Monday, February 4, 2019 9:45:00 AM EAT

Charbel Moussa added : "Our discovery clearly indicates that inhibition of USP13 is a strategic step to activate parkin and counteract alpha-synuclein de-ubiquitination, to increase toxic protein clearance" "Our next step is to develop a small molecule inhibitor of USP13 to be used in combination with nilotinib in order to maximize protein clearance in Parkinson's and other neurodegenerative diseases" External link

medicalxpress Monday, February 4, 2019 9:45:00 AM EAT



Key Titles and Phrases Count Lang Last Seen
investigator66.67%EN07/13/201613/07/2016
senior researcher33.33%EN07/12/201612/07/2016
Names Lang Count
Charbel MoussaEN75.00%
Charbel MoussaPT25.00%


<<10<12345678910>>>10
<<10<12345678910>>>10

Tools

Load latest edition

Saturday, September 19, 2020

7:34:00 PM EAT


Quotes... Explore Relations


EMM Visual Explorer